Myelodysplastic Syndrome

Obtain a peripheral smear, bone marrow aspirate and trephine biopsy, marrow blast assessment, conventional chromosome banding analysis, and myeloid molecular testing when MDS is suspected. Cytomorphologic abnormalities in blood and marrow and histologic findings in the core biopsy remain central to diagnosis, while clonal cytogenetic or molecular abnormalities refine classification and prognosis. ScienceDirect+1ScienceDirectMorphology, cytogenetics and classification of MDS - ScienceDirectScienceDirectCytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH) - ScienceDirect

Request marrow conventional karyotype at the initial diagnostic sampling; chromosome banding analysis is considered mandatory for WHO-HAEM5 or ICC classification and for IPSS-R/IPSS-M scoring. Clonal chromosomal abnormalities occur in approximately 40% to 45% of de novo MDS and up to 80% of therapy-related MDS, making therapy exposure history clinically consequential at presentation. ScienceDirectScienceDirectCytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH) - ScienceDirect

Use multiparameter flow cytometry as an adjunct rather than a replacement for morphology and cytogenetics. It can demonstrate quantitative and qualitative hematopoietic abnormalities and may establish an immunophenotypic abnormality when combined morphology and cytogenetics are nondiagnostic; interpret results in the full clinicopathologic context. ScienceDirect+1ScienceDirectDiagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome - ScienceDirectWileyDiagnostic flow cytometry for low‐grade myelodysplastic syndromes - Ogata - 2008 - Hematological Oncology - Wiley Online Library

Calculate IPSS-R at diagnosis using marrow blasts, cytogenetic abnormalities, and the degree of cytopenias. IPSS-M extends this framework by incorporating blood counts, marrow blasts, the five IPSS-R cytogenetic categories, 16 main-effect genes, and 15 residual genes; it was developed and validated in 3,711 patients. Wolters KluwerWolters KluwerEvaluation of new IPSS-Molecular model and... : Blood Science

Do not regard “lower-risk” as clinically uniform. Lower-risk disease often has lower immediate risk of death or AML evolution, but anemia, transfusion requirements, thrombocytopenia, neutropenia, and inflammatory complications may drive morbidity and mortality and should determine the intervention target. NatureNatureManagement of patients with lower-risk myelodysplastic syndromes | Blood Cancer Journal

Recognize molecularly defined patterns that alter counseling and management emphasis. SF3B1 mutation is strongly associated with ring sideroblasts, normal cytogenetics, and favorable disease characteristics, whereas TP53 mutations add adverse prognostic information beyond clinicopathologic variables. Nature+1NatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer JournalNatureDiagnostic algorithm for lower-risk myelodysplastic syndromes | Leukemia

For symptomatic anemia, treatment selection should account for symptoms and severity of cytopenias, disease characteristics, and erythropoietin levels. Erythropoiesis-stimulating agents are a principal initial option; lenalidomide is particularly relevant in patients with deletion 5q. BMJ+1BMJMyelodysplastic syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USNatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer Journal

For lower-risk anemia not adequately addressed by initial erythroid support, phenotype-directed options include luspatercept and imetelstat; the treatment sequence should also account for ring sideroblast/SF3B1 features, transfusion burden, prior therapies, and ongoing cytopenias. BMJ+2BMJMyelodysplastic syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USNatureManagement of patients with lower-risk myelodysplastic syndromes | Blood Cancer JournalNatureDiagnostic algorithm for lower-risk myelodysplastic syndromes | Leukemia

Consider immunosuppressive therapy with antithymocyte globulin, thrombopoiesis-stimulating agents, or a hypomethylating agent in selected lower-risk patients rather than treating all lower-risk disease identically. Use transfusions and antimicrobial therapy when clinically needed across risk categories. BMJ+1BMJMyelodysplastic syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USNatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer Journal

Refer transplant-eligible patients with higher-risk MDS for allogeneic hematopoietic stem-cell transplantation as soon as possible. Allogeneic transplantation remains the best curative option for higher-risk MDS, while nontransplant therapies are not curative. Nature+2NatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer JournalNatureImpact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes | Blood Cancer JournalNatureOutcome after allogeneic stem cell transplantation with ...

Use azacitidine or decitabine as disease-modifying therapy for higher-risk patients who are not transplant candidates and continue treatment if tolerated until disease progression. For a transplant candidate, hypomethylating therapy can be used as a bridge while donor identification, pretransplant assessment, and conditioning planning proceed. NatureNatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer Journal

Discuss prognosis in quantitative terms when counseling higher-risk patients. In a 2,045-patient higher-risk MDS cohort, median overall survival from diagnosis was 15.1 months; 2-year and 5-year overall survival were 32% and 15%, and cumulative AML transformation was 24% at 2 years and 29% at 5 years. These cohort-level estimates should not replace individualized IPSS-R/IPSS-M assessment. NatureNatureImpact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes | Blood Cancer Journal

At each treatment interval, track complete blood counts, transfusion requirement, infectious events, bleeding, and therapy tolerance. Cytopenia complications—including infection—account for substantial morbidity and mortality before AML transformation, so supportive measures should be adjusted as clinical events emerge. BMJ+1BMJMyelodysplastic syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice USNatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer Journal

Repeat marrow assessment with cytogenetics and molecular reassessment when there is an unexplained change in counts, suspected progression, loss of hematologic response, or concern for AML transformation. Karyotype abnormalities have independent prognostic importance and are required for IPSS-R/IPSS-M calculation, making clonal evolution clinically actionable. Wolters Kluwer+1Wolters KluwerEvaluation of new IPSS-Molecular model and... : Blood ScienceScienceDirectCytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH) - ScienceDirect

Use disease reassessment to revisit transplant eligibility rather than reserving transplant discussion for diagnosis alone. In higher-risk disease, transplant is the curative option; in lower-risk disease, escalating marrow blasts, progressive cytopenias, or unfavorable molecular evolution may change the risk-benefit balance toward disease-modifying therapy or transplant consultation. Nature+1NatureMyelodysplastic syndromes current treatment algorithm 2018 | Blood Cancer JournalNatureOutcome after allogeneic stem cell transplantation with ...